Market Research Logo

Hematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018

Hematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Hematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018 provides an overview of Hematology Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hematology Rapid Tests & Point of Care (POC) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hematology Rapid Tests & Point of Care (POC) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hematology Rapid Tests & Point of Care (POC) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Hematology Rapid Tests & Point of Care (POC) Overview
3 Products under Development
3.1 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
3.2 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment
3.3 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
3.4 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
3.5 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date
4 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies
4.1 Hematology Rapid Tests & POC Companies - Pipeline Products by Stage of Development
4.2 Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
5 Hematology Rapid Tests & Point of Care (POC) Companies and Product Overview
5.1 Beckman Coulter Inc Company Overview
5.2 BioMedomics Inc Company Overview
5.3 Biosurfit, SA Company Overview
5.4 Correlia Biosystems, Inc. Company Overview
5.5 DxDiscovery, Inc. Company Overview
5.6 Dynasil Corporation of America Company Overview
5.7 ET Healthcare, Inc. Company Overview
5.8 genedrive plc Company Overview
5.9 KeenCAT Technologies Company Overview
5.10 Ohio State University Company Overview
5.11 PortaScience Inc Company Overview
5.12 Siemens Healthcare GmbH Company Overview
5.13 T2 Biosystems Inc Company Overview
5.14 University of Glasgow Company Overview
5.15 University of Melbourne Company Overview
6 Hematology Rapid Tests & Point of Care (POC) - Recent Developments
6.1 Jun 25, 2018: Beckman Coulter Files a 510(k) Submission with the FDA for Its Early Sepsis Indicator
6.2 Jun 14, 2018: Consort Medical delivered another year of good growth in revenue and profit
6.3 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers
6.4 May 29, 2018: Akers Biosciences Announces Board Change
6.5 May 25, 2018: Akers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq
6.6 May 08, 2018: Quidel Announces First Quarter 2018 Financial Results
6.7 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results
6.8 May 03, 2018: Beckman Coulter Achieves CE Mark for Its Early Sepsis Indicator
6.9 May 03, 2018: Siemens Healthineers fully on track to meet the targets
6.10 Apr 27, 2018: Universal Biosensors releases Q1 FY2018 results - investing in new product development while building cash position
6.11 Apr 26, 2018: Akers Biosciences: Directorate Change
6.12 Apr 26, 2018: Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2018 and Declares a 13% Increase in Quarterly Cash Dividend
6.13 Apr 26, 2018: Consort Medical: Director Declaration
6.14 Apr 16, 2018: A high-sensitive blood test when it is safe to return to play after a sports-related concussion
6.15 Apr 12, 2018: Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
6.16 Apr 03, 2018: Akers Biosciences Reports Earnings for Fiscal Year 2017
6.17 Mar 14, 2018: EKF Diagnostics Holdings: 2017 Final results
6.18 Feb 28, 2018: Biohit Group Financial Statement Release 2017
6.19 Feb 27, 2018: Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results
6.20 Feb 21, 2018: Quidel Reports Fourth Quarter and Full Year 2017 Financial Results
6.21 Feb 20, 2018: Changes to Biohit Oyj’s Management Team
6.22 Feb 19, 2018: Quidel to establish new Business Service Centre in Galway city
6.23 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics
6.24 Jan 22, 2018: Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market
6.25 Jan 09, 2018: Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2018
6.26 Dec 07, 2017: NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology
6.27 Dec 05, 2017: Consort Medical: Interim results
6.28 Nov 29, 2017: Siemens plans to list Siemens Healthineers on Frankfurt Stock Exchange
6.29 Nov 15, 2017: Akers Biosciences Announces Q3 2017 Earnings
6.30 Nov 02, 2017: Bio-Rad Reports Third-Quarter 2017 Financial Results
6.31 Nov 01, 2017: Quidel Reports Third Quarter 2017 Financial Results
6.32 Oct 24, 2017: Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
6.33 Oct 24, 2017: Universal Biosensors releases Q3 2017 results - continued revenue growth strengthens net cash position
6.34 Oct 23, 2017: Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
6.35 Sep 11, 2017: EKF Diagnostics Holdings: Half Yearly Report
6.36 Sep 07, 2017: Akers Biosciences Hires Medical Device Specialist to Lead US Sales and Distribution
6.37 Aug 17, 2017: Biohit Group Half Year Financial Report 2017
6.38 Aug 15, 2017: Akers Biosciences: Financial Results for the Six Months Ended June 30, 2017
6.39 Aug 15, 2017: Akers Biosciences Announces Q2 2017 Earnings
6.40 Aug 08, 2017: Akers Biosciences Announces Board Changes
6.41 Aug 07, 2017: Rick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process
6.42 Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results
6.43 Aug 03, 2017: Akers Biosciences Announces Second Quarter Trading Update
6.44 Jul 31, 2017: Sysmex America Completes Expansion of Reagents Manufacturing Facility, Opens Doors to Latin American Sales Office in Doral, Florida
6.45 Jul 27, 2017: Abaxis Reports Financial Performance for the First Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
6.46 Jul 26, 2017: Quidel Reports Second Quarter 2017 Financial Results
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Table 2: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment
Table 3: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
Table 4: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
Table 5: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date
Table 6: Hematology Rapid Tests & POC Companies - Pipeline Products by Stage of Development
Table 7: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Table 8: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: DxH 900 - Early Sepsis Indicator - Product Status
Table 10: DxH 900 - Early Sepsis Indicator - Product Description
Table 11: BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Rapid Quantitative Heparin-Induced Thrombocytopenia (H.I.T.) Test - Product Status
Table 13: Rapid Quantitative Heparin-Induced Thrombocytopenia (H.I.T.) Test - Product Description
Table 14: Sickle SCAN - Product Status
Table 15: Sickle SCAN - Product Description
Table 16: Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview
Table 17: Spinit Device - Blood Quantitation Anemia Assay - Product Status
Table 18: Spinit Device - Blood Quantitation Anemia Assay - Product Description
Table 19: Spinit Device - Thrombocytopenia Assay - Product Status
Table 20: Spinit Device - Thrombocytopenia Assay - Product Description
Table 21: Correlia Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 22: Electrokinetic Lateral Flow Test - Product Status
Table 23: Electrokinetic Lateral Flow Test - Product Description
Table 24: DxDiscovery, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Diagnostic Assay - Sickle Cell Disease - Product Status
Table 26: Diagnostic Assay - Sickle Cell Disease - Product Description
Table 27: Dynasil Corporation of America Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Diagnostic Test - Hemophilia - Product Status
Table 29: Diagnostic Test - Hemophilia - Product Description
Table 30: ET Healthcare, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Pylon Assay - D-Dimer - Product Status
Table 32: Pylon Assay - D-Dimer - Product Description
Table 33: genedrive plc Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Genedrive - Factor V Leiden - Product Status
Table 35: Genedrive - Factor V Leiden - Product Description
Table 36: KeenCAT Technologies Pipeline Products & Ongoing Clinical Trials Overview
Table 37: HematoCAT - Product Status
Table 38: HematoCAT - Product Description
Table 39: Ohio State University Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Diagnostic Assay - Thrombotic Thrombocytopenic Purpura - Product Status
Table 41: Diagnostic Assay - Thrombotic Thrombocytopenic Purpura - Product Description
Table 42: PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 43: PortaWBC - Product Status
Table 44: PortaWBC - Product Description
Table 45: Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 46: Advia 120 Hematology System - IRF Test - Product Status
Table 47: Advia 120 Hematology System - IRF Test - Product Description
Table 48: ADVIA 120 Hematology System - MPC Test - Product Status
Table 49: ADVIA 120 Hematology System - MPC Test - Product Description
Table 50: Advia 120 Hematology System - MPM Test - Product Status
Table 51: Advia 120 Hematology System - MPM Test - Product Description
Table 52: ADVIA 2120 Hematology System - MPC Test - Product Status
Table 53: ADVIA 2120 Hematology System - MPC Test - Product Description
Table 54: Advia 2120 Hematology System - MPM Test - Product Status
Table 55: Advia 2120 Hematology System - MPM Test - Product Description
Table 56: ADVIA 2120i Hematology System - MPC Test - Product Status
Table 57: ADVIA 2120i Hematology System - MPC Test - Product Description
Table 58: ADVIA 2120i Hematology System - MPM Test - Product Status
Table 59: ADVIA 2120i Hematology System - MPM Test - Product Description
Table 60: T2 Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 61: T2HemoStat - Product Status
Table 62: T2HemoStat - Product Description
Table 63: T2MR Assay - Platelet Function Testing - Product Status
Table 64: T2MR Assay - Platelet Function Testing - Product Description
Table 65: University of Glasgow Pipeline Products & Ongoing Clinical Trials Overview
Table 66: Immunoassay - Haemoglobin - Product Status
Table 67: Immunoassay - Haemoglobin - Product Description
Table 68: University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview
Table 69: Thrombin Generation Assay - Product Status
Table 70: Thrombin Generation Assay - Product Description
Table 71: Glossary
1.2 List of Figures
Figure 1: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Figure 2: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment
Figure 3: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
Figure 4: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
Figure 5: Hematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook